CytomX Therapeutics, Inc.
7.8M
$1.01B
-33.83
$-0.13
No price alerts set. Add an alert to get notified!
-33.83
5.93
$-0.13
-17.54%
-22.79%
-25.67%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ATXS
Astria Therapeutics, Inc.
|
$12.58 | 0.00 | -5.88 | $718.13M | 0.02 |
|
AVBP
ArriVent BioPharma, Inc. Common Stock
|
$24.17 | -0.56% | -5.59 | $1.07B | 0.00 |
|
AVXL
Anavex Life Sciences Corp.
|
$4.66 | -1.06% | -10.39 | $432.78M | 0.00 |
|
DNA
Ginkgo Bioworks Holdings, Inc.
|
$6.81 | 0.81% | -1.21 | $421.40M | 0.82 |
|
ERAS
Erasca, Inc.
|
$13.07 | -3.26% | -29.75 | $4.05B | 0.14 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$3.99 | -1.24% | -4.15 | $1.32B | 0.07 |
|
MBX
MBX Biosciences, Inc. Common Stock
|
$28.91 | -2.98% | -12.14 | $971.24M | 0.00 |
|
MGTX
MeiraGTx Holdings plc
|
$7.64 | -0.62% | -3.67 | $615.35M | -2.17 |
|
MLTX
MoonLake Immunotherapeutics
|
$16.85 | 0.72% | -4.78 | $1.21B | 0.25 |
|
REPL
Replimune Group, Inc.
|
$7.22 | -1.84% | -2.12 | $596.63M | 0.37 |
* Peer stocks are selected based on market capitalization and sector
$8.21
$0.40
$0.02
0.51%
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
